- Home
- CPHC vs ALRN Comparison
CPHC vs ALRN Comparison
Compare CPHC & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPHC
- ALRN
- Stock Information
- Founded
- CPHC 1994
- ALRN 2001
- Country
- CPHC United States
- ALRN United States
- Employees
- CPHC N/A
- ALRN N/A
- Industry
- CPHC Services-Misc. Amusement & Recreation
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- CPHC Consumer Discretionary
- ALRN Health Care
- Exchange
- CPHC Nasdaq
- ALRN Nasdaq
- Market Cap
- CPHC 94.6M
- ALRN 76.9M
- IPO Year
- CPHC 1994
- ALRN 2017
- Fundamental
- Price
- CPHC $19.80
- ALRN $2.58
- Analyst Decision
- CPHC
- ALRN Strong Buy
- Analyst Count
- CPHC 0
- ALRN 1
- Target Price
- CPHC N/A
- ALRN $19.00
- AVG Volume (30 Days)
- CPHC 3.9K
- ALRN 87.4K
- Earning Date
- CPHC 11-07-2024
- ALRN 11-14-2024
- Dividend Yield
- CPHC 1.37%
- ALRN N/A
- EPS Growth
- CPHC N/A
- ALRN N/A
- EPS
- CPHC 0.94
- ALRN N/A
- Revenue
- CPHC $62,111,814.00
- ALRN N/A
- Revenue This Year
- CPHC N/A
- ALRN N/A
- Revenue Next Year
- CPHC N/A
- ALRN N/A
- P/E Ratio
- CPHC $21.65
- ALRN N/A
- Revenue Growth
- CPHC 0.13
- ALRN N/A
- 52 Week Low
- CPHC $14.27
- ALRN $1.61
- 52 Week High
- CPHC $30.25
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- CPHC 53.02
- ALRN 29.28
- Support Level
- CPHC $19.47
- ALRN $2.67
- Resistance Level
- CPHC $20.38
- ALRN $3.11
- Average True Range (ATR)
- CPHC 0.56
- ALRN 0.38
- MACD
- CPHC 0.03
- ALRN -0.15
- Stochastic Oscillator
- CPHC 55.10
- ALRN 4.85
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.